Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all

被引:43
|
作者
Grebely, Jason [1 ]
Hajarizadeh, Behzad [1 ]
Lazarus, Jeffrey V. [2 ]
Bruneau, Julie [3 ,4 ]
Treloar, Carla [5 ]
机构
[1] UNSW Sydney, Kirby Inst, Sydney, NSW, Australia
[2] Univ Barcelona, Barcelona Inst Global Hlth ISGlobal, Hosp Clin, Barcelona, Spain
[3] Ctr Hosp Univ Montreal, CHUM Res Ctr, Montreal, PQ, Canada
[4] Univ Montreal, Dept Family & Emergency Med, Fac Med, Montreal, PQ, Canada
[5] UNSW Sydney, Ctr Social Res Hlth, Sydney, NSW, Australia
基金
英国医学研究理事会;
关键词
HCV; Drug users; Injecting; Treatment; Care; Access; PWID; SUSTAINED VIROLOGICAL RESPONSE; PRESCRIPTION OPIOID INJECTION; HCV INFECTION; RISK-FACTORS; GLOBAL PREVALENCE; UNITED-STATES; PEER SUPPORT; LATE RELAPSE; HEALTH-CARE; NEW-YORK;
D O I
10.1016/j.drugpo.2019.07.016
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
There have been major strides towards the World Health Organization goal to eliminate hepatitis C virus (HCV) infection as a global public health threat. The availability of simple, well-tolerated direct-acting antiviral therapies for HCV infection that can achieve a cure in > 95% of people has provided an important tool to help achieve the global elimination targets. Encouragingly, therapy is highly effective among people receiving opioid agonist therapy and people who have recently injected drugs. Moving forward, major challenges include ensuring that new infections are prevented from occurring and that people who are living with HCV are tested, linked to care, treated, receive appropriate follow-up, and have equitable access to care. This editorial highlights key themes and articles in a special issue focusing on the elimination of HCV among people who inject drugs. An overarching consideration flowing from this work is how to ensure equitable access to HCV treatment and care for all. This special issue maps the field in relation to: HCV prevention; the cascade of HCV care; strategies to enhance testing, linkage to care, and treatment uptake; and HCV treatment and reinfection. In addition, papers draw attention to the 'risk environments' and socio-ecological determinants of HCV acquisition, barriers to HCV care, the importance of messaging around the side-effects of new direct-acting antiviral therapies, the positive transformative potential of treatment and cure, and the key role of community-based drug user organizations in the HCV response. While this special issue highlights some successful efforts towards HCV elimination among people who inject drugs, it also highlights the relative lack of attention to settings in which resources enabling elimination are scarce, and where elimination hopes and potentials are less clear, such as in many low and middle income countries. Strengthening capacity in areas of the world where resources are more limited will be a critical step towards ensuring equity for all so that global HCV elimination among PWID can be achieved.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 50 条
  • [21] Hepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion
    Chu, Carissa E.
    Wu, Feng
    He, Xi
    Zhou, Kali
    Cheng, Yu
    Cai, Weiping
    Geng, Elvin
    Volberding, Paul
    Tucker, Joseph D.
    OPEN FORUM INFECTIOUS DISEASES, 2016, 3 (02):
  • [22] Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence
    Hickman, Matthew
    De Angelis, Daniela
    Vickerman, Peter
    Hutchinson, Sharon
    Martin, Natasha Kaleta
    CURRENT OPINION IN INFECTIOUS DISEASES, 2015, 28 (06) : 576 - 582
  • [23] Differences in hepatitis C virus (HCV) testing and treatment by opioid, stimulant, and polysubstance use among people who use drugs in rural US communities
    Estadt, Angela T.
    Kline, David
    Miller, William C.
    Feinberg, Judith
    Hurt, Christopher B.
    Mixson, L. Sarah
    Friedmann, Peter D.
    Lowe, Kelsa
    Tsui, Judith I.
    Young, April M.
    Cooper, Hannah
    Korthuis, P. Todd
    Pho, Mai T.
    Jenkins, Wiley
    Westergaard, Ryan P.
    Go, Vivian F.
    Brook, Daniel
    Smith, Gordon
    Rice, Dylan R.
    Lancaster, Kathryn E.
    HARM REDUCTION JOURNAL, 2024, 21 (01)
  • [24] Modeling Hepatitis C Elimination Among People Who Inject Drugs in New Hampshire
    Blake, Andrew
    Smith, James E.
    JAMA NETWORK OPEN, 2021, 4 (08) : E2119092
  • [25] Hepatitis C diagnosis and treatment in people who use drugs: mind the gap in the linkage to care
    Taibi, C.
    Luzzitelli, I
    Comandini, U. Visco
    Girardi, E.
    Monacelli, G.
    Rapisarda, L. M.
    Garbuglia, A. R.
    Minosse, C.
    Guarrasi, V
    Vincenzi, L.
    Iacomi, F.
    D'Offizi, G.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (19) : 5913 - 5921
  • [26] Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs
    Treloar, Carla
    Hull, Peter
    Dore, Gregory J.
    Grebely, Jason
    DRUG AND ALCOHOL REVIEW, 2012, 31 (07) : 918 - 924
  • [28] Modelling the impact of HIV and hepatitis C virus prevention and treatment interventions among people who inject drugs in Kenya
    Stone, Jack
    Fraser, Hannah
    Walker, Josephine G.
    Mafirakureva, Nyashadzaishe
    Mundia, Bernard
    Cleland, Charles
    Bartilol, Kigen
    Musyoki, Helgar
    Waruiru, Wanjiru
    Ragi, Allan
    Bhattacharjee, Parinita
    Chhun, Nok
    Lizcano, John
    Akiyama, Matthew J.
    Cherutich, Peter
    Wisse, Ernst
    Kurth, Ann
    Luhmann, Niklas
    Vickerman, Peter
    AIDS, 2022, 36 (15) : 2191 - 2201
  • [29] Excluding people who use drugs or alcohol from access to hepatitis C treatments - Is this fair, given the available data?
    Grebely, Jason
    Haire, Bridget
    Taylor, Lynn E.
    Macneill, Paul
    Litwin, Alain H.
    Swan, Tracy
    Byrne, Jude
    Levin, Jules
    Bruggmann, Philip
    Dore, Gregory J.
    JOURNAL OF HEPATOLOGY, 2015, 63 (04) : 779 - 782
  • [30] Declining Incidence of Hepatitis C Virus Infection among People Who Inject Drugs in a Canadian Setting, 1996-2012
    Grebely, Jason
    Lima, Viviane Dias
    Marshall, Brandon D. L.
    Milloy, M-J
    DeBeck, Kora
    Montaner, Julio
    Simo, Annick
    Krajden, Mel
    Dore, Gregory J.
    Kerr, Thomas
    Wood, Evan
    PLOS ONE, 2014, 9 (06):